Skip to main content

Attovia Therapeutics, Inc.

ATTO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0002058707

In the last 90 days, Attovia Therapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 65 institutions reported holding it in 13F filings for Q3 2026, worth $693.4M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 20, 2026
$690.3M
Insider buysLast 90 days, $10.3M in total
1
Insider sellsLast 90 days, $2.25M in total
1
13F holdersQ3 2026, +65 vs. previous quarter
65
13F valueReported value at the end of Q3 2026
$693.4M
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, Q3 FY2026
$0
No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
1.59M
Shares sold short
Change
+134.4K
+9.3% vs. previous
Days to cover
4.50
At average daily volume

Superinvestors holding ATTO, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding ATTO at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Attovia Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 28, 2026 (view filing)5:38 PM ETAug 5-623 daysWalsh ColinDirectorPPurchase+585.0K$17.58+$10.3M+24.0%3.02M afterAmended2 lotsDuplicate filing
Aug 28, 2026 (view filing)5:38 PM ETAug 523 daysWalsh ColinDirectorSSale−105.8K$21.28−$2.25M−100.0%0 afterAmended23 lotsDuplicate filing
Aug 28, 2026 (view filing)5:38 PM ETAug 523 daysWalsh ColinDirectorPPurchase+105.8K$21.25+$2.25M–105.8K afterAmendedDerivative6 lotsDuplicate filing
Aug 28, 2026 (view filing)5:38 PM ETAug 5-623 daysGoldman Sachs & Co. LLC and 7 othersOther: Former 10% OwnerPPurchase+585.0K$17.58+$10.3M+24.0%3.02M afterAmended2 lots
Aug 28, 2026 (view filing)5:38 PM ETAug 523 daysGoldman Sachs & Co. LLC and 7 othersOther: Former 10% OwnerSSale−105.8K$21.28−$2.25M−100.0%0 afterAmended23 lots
Aug 28, 2026 (view filing)5:38 PM ETAug 523 daysGoldman Sachs & Co. LLC and 7 othersOther: Former 10% OwnerPPurchase+105.8K$21.25+$2.25M–105.8K afterAmendedDerivative6 lots
Aug 10, 2026 (view filing)4:12 PM ETAug 64 daysvenBio Global Strategic Fund IV, L.P.10% OwnerPPurchase+382.4K$17.00+$6.50M+10.1%4.18M after
Aug 7, 2026 (view filing)9:47 PM ETAug 61 dayRedmile Group, LLC and 2 others10% OwnerPPurchase+200.0K$17.00+$3.40M+25.5%982.9K after
Aug 7, 2026 (view filing)9:47 PM ETAug 61 dayRedmile Group, LLC and 2 others10% OwnerPPurchase+400.0K$17.00+$6.80M+51.1%1.18M after
Aug 7, 2026 (view filing)3:45 PM ETAug 61 daySanofi10% OwnerPPurchase+300.0K$17.00+$5.10M+38.3%1.08M after

Top 10 13F holders, Q3 2026

See all 65 holders

The largest institutional positions in Attovia Therapeutics, Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding ATTO in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Frazier Life Sciences Management, L.P.7,046,271$120.8M3.00%+7,046,271New
Goldman Sachs Group Inc5,391,772$92.4M0.01%+5,391,772New
venBio Partners LLC4,181,366$71.7M14.45%+4,181,366New
Deep Track Capital, LP3,207,138$55.0M0.93%+3,207,138New
EcoR1 Capital, LLC2,024,010$34.7M1.71%+2,024,010New
Nextech Invest, Ltd.1,835,139$31.5M1.41%+1,835,139New
Cormorant Asset Management, LP1,788,815$30.7M2.06%+1,788,815New
Redmile Group, LLC1,163,587$19.9M1.46%+1,163,587New
Commodore Capital LP1,160,000$19.9M1.54%+1,160,000New
Sanofi1,082,855$18.6M2.95%+1,082,855New

Holders of 5% or more of ATTO

See all 5 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Attovia Therapeutics, Inc..

Largest holders of ATTO from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Frazier Life Sciences Public Fund, L.P.13D13.50%6.15M sharesNewAug 11, 20261 filingAug 11, 2026SEC
venBio Global Strategic Fund IV, L.P.13G9.20%4.18M sharesNewNov 16, 20261 filingNov 16, 2026SEC
Deep Track Capital, LP13G7.45%3.21M sharesNewAug 12, 20261 filingAug 12, 2026SEC
Alamar HoldCo, LLC13G7.10%3.23M sharesNewNov 13, 20261 filingNov 13, 2026SEC
Goldman Sachs Group Inc13G6.70%3.04M sharesNewNov 13, 20261 filingNov 13, 2026SEC